
SCHAUMBURG, Ill., Feb. 20 (UPI) -- Heparin manufacturer APP Pharmaceuticals Inc. is increasing production to ward off shortages in the wake of troubles at rival Baxter International Inc.
The U.S. Food and Drug Administration is investigating Baxter's version of the product, implicated in four deaths and 350 reports of allergic reactions this year.
In response, Baxter stopped making the blood thinner, which is used before kidney dialysis and heart surgeries.
To keep supplies in place, the FDA sent inspectors to China to inspect APP Pharmaceuticals' supplier and is acting to approve their new production lines, while the company positions itself to claim more of the heparin market, The Wall Street Journal reported.
The FDA said Wednesday it also was inspecting a Baxter plant in Cherry Hill, N.J., and a Scientific Protein Laboratories LLC plant in Waunakee, Wis., which supplies Baxter. A team will be sent to inspect their Chinese supplier, the FDA announced.
Major purchasers, such as Fresenius Medical Care AG, are making the switch to APP Pharmaceuticals' heparin. "We're no longer ordering Baxter heparin at this point," said Mark Moreau, senior director of materials management at Fresenius.
Before the crisis, Baxter and APP Pharmaceuticals each produced roughly half the nation's heparin supply.
|
|
|
|
|
|
| Additional Business News Stories | |
HAVANA, May 25 (UPI) --
Cuba is reportedly sitting on vast underwater oil and gas reserves, but none came up in the latest exploration, a joint Chinese-Spanish undertaking.
|
LONDON, May 25 (UPI) --
Military pilot training and training aircraft were in the news this week, with European companies reaping more than $3 billion in contracts.
|
First-time buyers are driving the expectations that a recovery has begun. Their numbers and market share are growing despite financing roadblocks and competition with investors for entry-level homes. ...
|
The photos are familiar, but the captions are not, as economic tension skips across the continent of Europe.
|
| Stories | Photos | People | Comments |
View Caption